Protara Therapeutics Q2 2022 net loss $8.5M ($0.80/share); cash $112.8M

Protara Therapeutics, Inc.

2022-Q2 EPS reported -$1.71

Net loss of $8.5M ($0.80 per share) vs $12.8M ($1.14) in Q2 2021.
Cash, cash equivalents and marketable debt securities of $112.8M as of June 30, 2022.
R&D expenses decreased to $3.1M from $5.9M; G&A decreased to $5.6M from $6.9M.
ADVANCED-1 Phase 1 trial of TARA-002 in NMIBC enrollment progressing; Trials in Progress poster presented at ASCO June 2022.
EMA granted orphan drug designation to TARA-002 for lymphatic malformations; Phase 2 trial planned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.